Per Norlén

Title: Per Norlén: Innovator in Bispecific Polypeptides

Introduction

Per Norlén, an accomplished inventor based in Lund, Sweden, has made significant contributions to the field of biotechnology. His innovative work primarily focuses on the development of bispecific polypeptides, which hold promise for advanced therapeutic applications.

Latest Patents

Norlen holds a patent for bispecific polypeptides against CD137. This invention involves creating polypeptides that consist of a first binding domain, B1, which specifically binds to CD137, and a second binding domain, B2, designed to attach to tumour cell-associated antigens. Additionally, the patent includes pharmaceutical compositions containing these bispecific polypeptides and their uses in medical treatments.

Career Highlights

Currently, Per Norlén is associated with Alligator Bioscience AB, a company known for its pioneering work in cancer immunotherapy. His expertise in the development of novel therapeutic agents has positioned him as a key player within the organization.

Collaborations

Throughout his career, Norlén has collaborated with notable colleagues, including Eva Dahlén and Peter Ellmark. Their joint efforts reflect a strong commitment to advancing research in the field of immunotherapies, showcasing the importance of teamwork in innovation.

Conclusion

Per Norlén's work exemplifies the potential of innovative inventions in biotechnology. His contributions not only enhance our understanding of bispecific polypeptides but also pave the way for new treatment avenues in the fight against cancer. Through his ongoing efforts at Alligator Bioscience AB, he continues to be a driving force in this vital area of research.